Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Year: 2018
Type: article
Abstract: The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.
Source: Diabetes Care
DOI: 10.2337/dci18-0033
Institutions: University of Leicester, Leicester General Hospital, Duke University, Duke Medical Center, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Yale University, Universitair Ziekenhuis Leuven, KU Leuven, King's College London, University of Copenhagen, Steno Diabetes Center Copenhagen, Aristotle University of Thessaloniki, Harvard University, Massachusetts General Hospital, University of North Carolina at Chapel Hill
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: U.S. Department of Health and Human Services, American Diabetes Association, Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Sanofi, Gilead Sciences, Intarcia Therapeutics, MannKind Corporation, Steno Diabetes Center Copenhagen, European Foundation for the Study of Diabetes, Daewoo Shipbuilding & Marine Engineering, Novo Nordisk, Servier, Mitsubishi Tanabe Pharma Corporation, National Institutes of Health, Takeda Pharmaceuticals International, National Center for Advancing Translational Sciences
OpenAlex ID: W2894993577